Home » Blog
affordable care act sympsoium obamacare narrow networks reference pricing aca contraceptive exchange health reform health insurance exchanges marketplace fqhc safety net decision making patient engagement electronic health records cms electronic medical records health care cost medicaid michigan small business mental health oregon depression readmissions aco health care costs costs medicare health policy exchanges politics wellness programs rules election courts coverage dual-eligible funding cheboygan memorial access communication scotus employers poverty variation cost use quality research policy health insurance acos hmos essential benefits reform sgr congress drugs class long term care va e-prescribing emrs patient safety states for-profit nonprofit block grant tanf welfare reform hospice end of life non-profit evidence-based care waste washtenaw county uninsured population health managed care cancer end-of-life care individual mandate ryan proposal obesity pharmaceutical industry r & d comparative effectiveness research evidence based care quality improvement collaborative quality initiatives cqi pharmaceuticals regulations prematurity heath reform antibiotics overuse geographic variation medical appropriateness health websites imrt radiation therapy medical errors constitutionality translate health care economics rationing insurance regulation incentives cardiology pcmh health disparities british health care system guidelines radiology pain early childhood physician employment dartmouth atlas cover michigan health care coverage insurance preventive care public health
For years, many in the health policy world have talked about the emphasis that pharmaceutical manufacturers were putting on “me too” drugs – drugs that are structurally similar to existing drugs with only subtle differences. And for a long time, I have been reading articles about the lack of new drugs in the drug development pipeline – especially blockbuster drugs that break new ground in the treatment of disease.
Today, we are releasing our 2010 report on health care coverage in Michigan. This report includes comprehensive data on the uninsured, publicly, privately insured and the safety net. In addition, we have included a final chapter on what could be the impact of health reform on coverage in Michigan. The 2010 report principally includes data from 2007/8, the most recently available comprehensive data on health care coverage in the U.S. and Michigan.